pembrolizumab,toripalimab,nivolumab,ipilimumab,Atezolizumab,durvalumab,Cisplatin,Vinorelbine,Gemcitabine,Docetaxel,Pemetrexed,Carboplatin,Paclitaxel
merck,Roche,BMS,Coherus,Junshi Biosciences,Astrazeneca
['lcsm,(-blcsm)']
an awesome talk by on periop io #asco23 is neoadj io better than adj io? encouraging signal for os benefit favoring neoadj io
any added contribution of adj io? long-term f/u and rct needed
is there a role of io w/ targetable mutation?
#lcsm 
Assistant Prof | Thoracic Oncology & Phase-I @karmanoscancer | EIC @BTFCancerNews | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb | Tweets my own